(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Latest News Releases From The Newsroom

SEC Charges Former Pfizer Statistician with Insider Trading Ahead of COVID-19 Announcement

June 29th, 2023

Employee and friend traded ahead of Pfizer’s “game-changer” announcement on the success of its Paxlovid trial FOR IMMEDIATE RELEASE 2022-123 Washington D.C. / CRWE PRESS RELEASE / June 29, 2023 -  The Securities and Exch. Read more

BREAKING: BioXcel's Regulatory Inquiry Status Sends Shares Tumbling

June 29th, 2023

Shares of BioXcel Therapeutics, Inc.? (Nasdaq: BTAI) plunged by over 50% in premarket trading following the company's disclosure of a regulatory inquiry into the development of BXCL501, as revealed in a regulatory filing with the SEC. Despite this. Read more

Joby's Pre-Market Surge, Nano Dimension's Milestone Quarter: What You Need to Know

June 29th, 2023

Shares of Joby Aviation, Inc. (NYSE: JOBY) experienced a significant surge of over 10% in pre-market trading following the announcement of an equity investment by SK Telecom Co., Ltd.? (NYSE: SKM), a prominent telecommunications company in South Kore. Read more

Earnings Beat: BlackBerry, Greenbrier, and Acuity Brands in the Spotlight

June 29th, 2023

Shares of BlackBerry Limited (NYSE: BB) experienced a significant surge of over 10% in pre-market trading following the release of better-than-expected financial results. The company delivered a surprise profit for the first quarter of fiscal 2024. Read more

Bullishness: ZI, GPC, SQSP, DE, VVI, WIX, ARRY, GDDY - Top Buy Ratings

June 29th, 2023

ZoomInfo Technologies Inc. (Nasdaq: ZI), a leading provider of go-to-market intelligence solutions, received coverage initiation from Needham with a Buy rating and a price target of $35.  Despite closing at $25.61 on Wednesday, the stated pri. Read more

FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes

June 28th, 2023

Silver Spring, MD / CRWE PRESS RELEASE / June 28, 2023 -  Today, the U.S. Food and Drug Administration approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for the treat. Read more

Gilead Boosts Stake In AlloVir; Significant Contracts for RTX and Textron

June 28th, 2023

Biopharmaceutical leader Gilead Sciences, Inc. (Nasdaq: GILD) has disclosed its acquisition of 2,930,870 shares of AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, in a regulatory filing FORM 4 with the SEC. The shares were a. Read more

Micron Q3 Beats Estimates, Concentrix Lowers FY23 Revenue Forecast

June 28th, 2023

Shares of Micron Technology, Inc. (Nasdaq: MU) surged in after-hours trading following the release of its better-than-expected financial results. In the third quarter of fiscal 2023, Micron reported a loss of $1.43 per share and revenue of $3.752 . Read more

Breaking: General Mills and Roivant Sciences - Earnings Reaction

June 28th, 2023

General Mills, Inc. (NYSE: GIS) released its fourth-quarter fiscal 2023 earnings report, surpassing the consensus estimates for earnings per share (EPS).  The company reported an EPS of $1.12, exceeding the consensus of $1.07. However, its sa. Read more

Pfizer, OPKO Health: FDA OKs GHD Treatment; Eton Pharma Faces Regulatory Setbacks

June 28th, 2023

Pfizer Inc. (NYSE: PFE) and  OPKO Health Inc. (Nasdaq: OPK) said that the  U.S. Food and Drug Administration  (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly treatment for pediatric patients with growth hormone deficiency (G. Read more